Clinical Study of Clinical Efficacy and Tolerability of hMG-IBSA s.c.in Women Undergoing COH in an ART Programme (IVF).

Inclusion Criteria: Women undergoing ovarian stimulation for IVF with or without ICSI (intracytoplasmic sperm injection) and with the following characteristics: Voluntary given informed consent to study participation in writing encompassing consent to data recording and verification procedures; > 18/= and < 37 years old; BMI between 18 and 28 kg/m2; Less than 3 previous completed IVF cycles; Basal FSH level less than 10 IU/L once within 6 months prior to the study; Within 12 month of the beginning of the study, uterine cavity consistent with expected normal function as assessed through a hysterosalpingogram, or sonohysterogram, or hysteroscopic examination or TVUS; Normal or clinically insignificant haematology and blood chemistry values. Exclusion Criteria: Primary ovarian failure or women known as poor responders; Signs of PCO, according to the Rotterdam Criteria; At least one ovary inaccessible for oocyte retrieval; One or more ovarian cysts > 10 mm; Hydrosalpinx that have not been surgically removed or ligated; Stage III or IV endometriosis; Patients affected by pathologies associated with any contraindication of being pregnant; Hypersensitivity to the study medication; Abnormal bleeding of undetermined origin; Uncontrolled thyroid or adrenal dysfunction; Neoplasias; PAP smear III within the last 2 years; Severe impairment of the renal and/or hepatic functions; Lactation; Hyperprolactinaemia; Participation in a concurrent clinical trial or in another trial within the past four weeks; Use of concomitant medication that might interfere with study evaluations.